Personal information

No personal information available

Activities

Collapse all

Employment (1)

Nanjing University of Chinese Medicine: Nanjing, Jiangsu, CN

2020-01-01 to present | Professor, Chief Physician (Cancer Center)
Employment
Source: Self-asserted source
SHU-KUI QIN

Education and qualifications (2)

China Europe International Business School: Pudong, Shanghai, CN

2004-06 to 2007-06 | EMBA (Medical MBA)
Education
Source: Self-asserted source
SHU-KUI QIN

Second Military Medical University: Shanghai, Shanghai, CN

1985-07-01 to 1988-07-01 | M.D. (Hematology & Oncology)
Education
Source: Self-asserted source
SHU-KUI QIN

Professional activities (2)

Chineser Society of Clinical Oncology: Bejing , Beijing, CN

1997-04-30 to present | Active member (CSCO Council)
Membership
Source: Self-asserted source
SHU-KUI QIN

Nanjing University of Chinese Medicine: Nanjing, Jiangsu, CN

1997-01-01 to present | Professor (Clinical Medicine)
Invited position
Source: Self-asserted source
SHU-KUI QIN

Works (35)

Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer

ESMO Gastrointestinal Oncology
2024-12 | Journal article
DOI: 10.1016/j.esmogo.2024.100095
Contributors: Z.A. Wainberg; P.C. Enzinger; S. Qin; K. Yamaguchi; J. Wang; X. Zhou; A. Gnanasakthy; K. Taylor; A. Yusuf; I. Majer et al.
Source: check_circle
Crossref

Data from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.c.6698131
Contributors: Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang et al.
Source: check_circle
Crossref

Data from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.c.6698131.v3
Contributors: Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang et al.
Source: check_circle
Crossref

Figure S1 from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27031711.v1
Contributors: Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang et al.
Source: check_circle
Crossref

Figure S1 from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27031711
Contributors: Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang et al.
Source: check_circle
Crossref

Supplementary Tables 1 from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27031708.v1
Contributors: Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang et al.
Source: check_circle
Crossref

Supplementary Tables 1 from Multicenter randomized double-blind phase III trial of donafenib in progressive radioactive iodine-refractory differentiated thyroid cancer

2024-09-16 | Preprint
DOI: 10.1158/1078-0432.27031708
Contributors: Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang et al.
Source: check_circle
Crossref

A phase 4 study to evaluate the safety of fruquintinib in Chinese patients in real-world clinical practice

2024-04-07 | Other
DOI: 10.1093/oncolo/oyae073
Contributors: Shukui Qin; Jin Li; Zhiqiang Wang; Haijun Zhong; Yifu Fu; Chen Zhang; Zuoxing Niu; Shujun Yang; Tao Zhang; Liangjun Zhu et al.
Source: check_circle
Crossref

Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer

Journal of Clinical Oncology
2023-11-20 | Journal article
DOI: 10.1200/JCO.22.02630
Contributors: Shukui Qin; Jin Li; Yuxian Bai; Zishu Wang; Zhendong Chen; Ruihua Xu; Jianming Xu; Hongmei Zhang; Jia Chen; Ying Yuan et al.
Source: check_circle
Crossref

Data from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer

2023-08-01 | Preprint
DOI: 10.1158/1078-0432.c.6698131.v2
Contributors: Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang et al.
Source: check_circle
Crossref

Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer

2023-08-01 | Preprint
DOI: 10.1158/1078-0432.23814737.v1
Contributors: Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang et al.
Source: check_circle
Crossref

Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer

2023-08-01 | Preprint
DOI: 10.1158/1078-0432.23814737
Contributors: Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang et al.
Source: check_circle
Crossref

Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Clinical Cancer Research
2023-08-01 | Journal article
DOI: 10.1158/1078-0432.CCR-22-3613
Contributors: Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang et al.
Source: check_circle
Crossref

Supplementary Tables 1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer

2023-08-01 | Preprint
DOI: 10.1158/1078-0432.23814734
Contributors: Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang et al.
Source: check_circle
Crossref

Supplementary Tables 1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer

2023-08-01 | Preprint
DOI: 10.1158/1078-0432.23814734.v1
Contributors: Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang et al.
Source: check_circle
Crossref

Data from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer

2023-06-15 | Preprint
DOI: 10.1158/1078-0432.c.6698131.v1
Contributors: Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang et al.
Source: check_circle
Crossref

Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer

2023-06-15 | Preprint
DOI: 10.1158/1078-0432.23523601
Contributors: Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang et al.
Source: check_circle
Crossref

Figure S1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer

2023-06-15 | Preprint
DOI: 10.1158/1078-0432.23523601.v1
Contributors: Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang et al.
Source: check_circle
Crossref

Supplementary Tables 1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer

2023-06-15 | Preprint
DOI: 10.1158/1078-0432.23523598
Contributors: Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang et al.
Source: check_circle
Crossref

Supplementary Tables 1 from Multicenter Randomized Double-Blind Phase III Trial of Donafenib in Progressive Radioactive Iodine-Refractory Differentiated Thyroid Cancer

2023-06-15 | Preprint
DOI: 10.1158/1078-0432.23523598.v1
Contributors: Yansong Lin; Shukui Qin; Hui Yang; Feng Shi; Aimin Yang; Xingmin Han; Bin Liu; Zhiyong Li; Qinghai Ji; Lijun Tang et al.
Source: check_circle
Crossref

Reply to T.A. Lin et al

Journal of Clinical Oncology
2023-06-01 | Journal article
DOI: 10.1200/JCO.23.00482
Contributors: Shukui Qin
Source: check_circle
Crossref

Impact of primary tumor side on clinical outcomes of first-line cetuximab plus FOLFOX-4 in RAS wild-type metastatic colorectal cancer

Future Oncology
2023-05 | Journal article
DOI: 10.2217/fon-2022-1068
Contributors: Shukui Qin; Tianshu Liu; Jianming Xu; Qi Li; Ying Cheng; Aimar Zhang; Regina Esser; Helena Chang; Jin Li
Source: check_circle
Crossref

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

Journal of Clinical Oncology
2023-03-01 | Journal article
DOI: 10.1200/JCO.22.00620
Contributors: Shukui Qin; Zhendong Chen; Weijia Fang; Zhenggang Ren; Ruocai Xu; Baek-Yeol Ryoo; Zhiqiang Meng; Yuxian Bai; Xiaoming Chen; Xiufeng Liu et al.
Source: check_circle
Crossref

Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

Journal of Clinical Oncology
2021-09-20 | Journal article
DOI: 10.1200/JCO.21.00163
Contributors: Shukui Qin; Feng Bi; Shanzhi Gu; Yuxian Bai; Zhendong Chen; Zishu Wang; Jieer Ying; Yinying Lu; Zhiqiang Meng; Hongming Pan et al.
Source: check_circle
Crossref

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

Journal of Clinical Oncology
2021-09-20 | Journal article
DOI: 10.1200/JCO.20.03555
Contributors: Robin Kate Kelley; Bruno Sangro; William Harris; Masafumi Ikeda; Takuji Okusaka; Yoon-Koo Kang; Shukui Qin; David W.-M. Tai; Ho Yeong Lim; Thomas Yau et al.
Source: check_circle
Crossref

Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer

OncoTargets and Therapy
2021-08 | Journal article
DOI: 10.2147/OTT.S307273
Contributors: Shukui Qin; Rui-Hua Xu; Lin Shen; Jianming Xu; Yuxian Bai; Lei Yang; Yanhong Deng; Zhen-Dong Chen; Haijun Zhong; Hongming Pan et al.
Source: check_circle
Crossref

Atezolizumab and Bevacizumab for Hepatocellular Carcinoma: Mechanism, Pharmacokinetics and Future Treatment Strategies

Future Oncology
2021-06 | Journal article
DOI: 10.2217/fon-2020-1290
Contributors: Xiufeng Liu; Yi Lu; Shukui Qin
Source: check_circle
Crossref

Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study

Drug Design, Development and Therapy
2021-05 | Journal article
DOI: 10.2147/DDDT.S304857
Contributors: Hui Li; Shukui Qin; Ying Liu; Zhendong Chen; Zhenggang Ren; Jianping Xiong; Zhiqiang Meng; Xiao Zhang; Linna Wang; Xiaojing Zhang et al.
Source: check_circle
Crossref

<p>A retrospective six-patient series of apatinib for the treatment of persistent or recurrent carcinoma of the cervix</p>

OncoTargets and Therapy
2019-07 | Journal article
DOI: 10.2147/OTT.S212536
Contributors: Chao Chen; Shukui Qin; Zixiong Li; Xianwen Luo; Yu Zhang; Jue Zhang; Xiufeng Liu
Source: check_circle
Crossref

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung

OncoTargets and Therapy
2018-11 | Journal article
DOI: 10.2147/OTT.S161506
Contributors: Shun Lu; Wei Li; Caicun Zhou; Cheng-Ping Hu; Shukui Qin; Gang Cheng; Jifeng Feng; Jie Wang; Agnieszka Cseh; Barbara Peil et al.
Source: check_circle
Crossref

Local analgesic effect of a bioadhesive barrier-forming oral liquid in cancer patients with oral mucositis caused by chemotherapy and/or radiotherapy: a randomized multicenter, single-use, positive-controlled, open-label study

OncoTargets and Therapy
2018-11 | Journal article
DOI: 10.2147/OTT.S185915
Contributors: Yuan Cheng; Shu Kui Qin; Yan Ping Chen; Li Hua Dong; Xiang Dong Sun; Shi Ying Yu; Shi Kai Wu
Source: check_circle
Crossref

Apatinib targets both tumor and endothelial cells in hepatocellular carcinoma

Cancer Medicine
2018-09 | Journal article
DOI: 10.1002/cam4.1664
Contributors: Chaoxu Yang; Shukui Qin
Source: check_circle
Crossref

Treatment with olaparib monotherapy for BRCA2-mutated refractory intrahepatic cholangiocarcinoma: a case report

OncoTargets and Therapy
2018-09 | Journal article
DOI: 10.2147/OTT.S176914
Contributors: Yuan Cheng; Juan Zhang; Shu kui Qin; Hai qing Hua
Source: check_circle
Crossref

The synergistic effects of Apatinib combined with cytotoxic chemotherapeutic agents on gastric cancer cells and in a fluorescence imaging gastric cancer xenograft model

OncoTargets and Therapy
2018-05 | Journal article
DOI: 10.2147/OTT.S159935
Contributors: Jiuhuan Feng; Shukui Qin
Source: check_circle
Crossref

Multiline treatment combining apatinib with toptecan for platinum-resistant recurrent ovarian cancer patients: a report of three cases

OncoTargets and Therapy
2018-04 | Journal article
DOI: 10.2147/OTT.S158141
Contributors: Yuan Cheng; Juan Zhang; Haiyun Geng; Shukui Qin; Haiqing Hua
Source: check_circle
Crossref

Peer review (1 review for 1 publication/grant)

Review activity for Nature reviews. (1)
How many people are using ORCID?